ArticleCureus2025
Botulinum Toxin for Pediatric Vocal Cord Dysfunction: A Case Series.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Vocal cord dysfunction (VCD) in children is a rare but challenging airway disorder characterized by inappropriate vocal fold adduction during inspiration. In pediatric populations, it is often associated with neurologic comorbidities or refractory symptoms that do not respond to conventional therapies such as voice therapy or medical management. Botulinum toxin (BTX) has emerged as a potential therapeutic option due to its ability to transiently weaken overactive laryngeal muscles while preserving essential airway and phonatory function. However, evidence on its efficacy and safety in children remains limited. Methods We conducted a retrospective case series of 10 pediatric patients with confirmed VCD treated with BTX at a tertiary pediatric otolaryngology center between 2021 and 2024. All patients underwent pre- and post-treatment laryngoscopy with exercise laryngoscopy when feasible. Swallowing function was assessed via fiberoptic endoscopic evaluation of swallowing (FEES) or modified barium swallow studies. Results Ten patients (six female patients and four male patients; ages 12 days to 17 years) met the inclusion criteria. Primary indications included refractory inspiratory stridor (n = 10), severe dysphagia (n = 6), and failed conservative management. Four patients had tracheostomies for severe VCD-related obstruction; all were ultimately decannulated, although three required adjunctive airway procedures. BTX doses ranged from 10 to 50 units, titrated progressively over multiple sessions based on response and tolerance, targeting interarytenoid, thyroarytenoid, and lateral cricoarytenoid muscles. Post-treatment laryngoscopy showed improved glottic opening in nine (90%) patients. Non-tracheostomized patients showed marked improvement in dyspnea and swallowing function. Transient mild voice changes occurred in three patients but resolved within 4-6 weeks, and no aspiration events were observed. Conclusion BTX demonstrates significant efficacy in pediatric VCD management, particularly in cases with neurologic etiology and severe symptoms refractory to conservative therapy. Objective measures support its role in improving glottic function and facilitating decannulation in appropriately selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.